Independant Safety Panel may of suggested data indicates an early stop on efficacy .
MSB then has decision to make after talking to FDA and asking if the amount of data gathered is sufficient for approval or only enough for emergency use?
Does MSB and NIH continue trial to gather more data?
Could be the circumstances here?
Maybe SI notified by a Major Pharma of intention to lodge a takeover? Friendly or Hostile (first of a few I hope as value setting).
Could be another?
Ann: Trading halt, page-94
-
- There are more pages in this discussion • 703 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
99.0¢ |
Change
0.030(3.13%) |
Mkt cap ! $1.130B | |||
| Open | High | Low | Value | Volume |
| 96.5¢ | $1.03 | 96.5¢ | $4.704M | 4.708M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 87395 | 98.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.00 | 274051 | 2 |
View Market Depth
| Last trade - 16.10pm 14/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |